ArticleThe EMBO journal1997
tom-1, a novel v-Myb target gene expressed in AMV- and E26-transformed myelomonocytic cells.
Article in The EMBO journal, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.Journal of virology · 2026Article
- Broad-spectrum chemicals block ROS detoxification to prevent plant fungal invasion.Current biology : CB · 2022Article
- Structure of Myosin VI/Tom1 complex reveals a cargo recognition mode of Myosin VI for tethering.Nature communications · 2019Article
- Myosin VI and its cargo adaptors - linking endocytosis and autophagy.Journal of cell science · 2013Review
- CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP).The Journal of biological chemistry · 2010Article
- Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding rna transcription and is disrupted by oncogenic mutations of v-myb.The Journal of biological chemistry · 2009Article
- Diversification of TOLLIP isoforms in mouse and man.Mammalian genome : official journal of the International Mammalian Genome Society · 2009Article
- Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response.Mammalian genome : official journal of the International Mammalian Genome Society · 2008Article
- C/EBPbeta induces chromatin opening at a cell-type-specific enhancer.Molecular and cellular biology · 2008Article
- The promoter regions of the Myb-regulated Adora2B and Mcm4 genes co-localize with origins of DNA replication.BMC molecular biology · 2007Article
- v-Myb represses the transcription of Ets-2.Oncogene · 2007Article
- Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene.Nucleic acids research · 2007Article
- The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells.Oncogene · 2006Article
- The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors.Molecular and cellular biology · 2006Article
- v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter.Molecular and cellular biology · 2005Article
- Article
- The glioma-amplified sequence 41 gene (GAS41) is a direct Myb target gene.Nucleic acids research · 2004Article
- Article
- Identification and characterization of the Myb-inducible promoter of the chicken adenosine receptor 2B gene.Oncogene · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The retroviral oncogene v-myb is a mutated and truncated version of the c-myb proto-oncogene and encodes a transcription factor (v-Myb) that specifically transforms myelomonocytic cells. Two different variants of v-myb, transduced independently by the oncogenic chicken retroviruses AMV and E26, have been characterized. It is believed that both variants of v-Myb transform myelomonocytic cells by affecting the expression of specific genes; however, no target genes common to both oncogenic viruses have been identified. Here, we describe the identification of a novel v-Myb target gene, designated as tom-1 (target of myb 1). The tom-1 gene has two promoters, one of which is Myb-inducible. tom-1 is expressed at elevated levels in AMV-transformed as well as in E26-transformed myeloid cells. We show that tom-1 activation by v-Myb does not require de novo protein synthesis and that the Myb-inducible tom-1 promoter contains a functional Myb binding site. Thus, tom-1 is the first example of a direct target gene for both oncogenic forms of the v-myb gene. Further analysis of the Myb-inducible tom-1 promoter shows that a C/EBP binding site is juxtaposed to the Myb binding site and that C/EBP is required for the Myb-dependent activation of the promoter. Together with previous work our results suggest that C/EBP may be a general cooperation partner for v-Myb in myelomonocytic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.